Lithium ions have a potent and selective inhibitory effect on cyclic GMP formation stimulated by neurotensin, angiotensin II and bradykinin

Shigenobu Kanba, Michael Pfenning, Kiyoko S. Kanba, Elliott Richelson

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The effect of lithium ion (Li+) on receptor-mediated synthesis of cyclic GMP, a putative second messenger, was examined using intact murine neuroblastoma cells (clone N1E-115). Lithium chloride potently inhibited cyclic GMP formation stimulated by the neuropeptides, neurotensin, angiotensin II and bradykinin in an identical concentration-dependent (IC50s of around 12 mM), saturable and reversible manner. In the presence of veratridine, an alkaloid which by stimulating sodium channels can increase Li+ entry into the cells, Li+ inhibited neurotensin-stimulated cyclic GMP formation more potently (IC50 = 7 mM). No effect of Li+ was observed on phosphodiesterase (EC 3.1.4.17) activity. These results suggest that Li+ may interfere with the function of these receptors through its inhibitory effect at a common site in the pathway of receptor-mediated cyclic GMP formation.

Original languageEnglish (US)
Pages (from-to)111-116
Number of pages6
JournalEuropean Journal of Pharmacology
Volume126
Issue number1-2
DOIs
StatePublished - Jul 15 1986

Fingerprint

Neurotensin
Cyclic GMP
Bradykinin
Lithium
Angiotensin II
Ions
Veratridine
Lithium Chloride
Sodium Channels
Phosphoric Diester Hydrolases
Second Messenger Systems
Neuropeptides
Neuroblastoma
Alkaloids
Inhibitory Concentration 50
Clone Cells

Keywords

  • Angiotensin II
  • Bradykinin
  • Cyclic GMP
  • Lithium
  • Neurotensin
  • Phosphodiesterase

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Lithium ions have a potent and selective inhibitory effect on cyclic GMP formation stimulated by neurotensin, angiotensin II and bradykinin. / Kanba, Shigenobu; Pfenning, Michael; Kanba, Kiyoko S.; Richelson, Elliott.

In: European Journal of Pharmacology, Vol. 126, No. 1-2, 15.07.1986, p. 111-116.

Research output: Contribution to journalArticle

Kanba, Shigenobu ; Pfenning, Michael ; Kanba, Kiyoko S. ; Richelson, Elliott. / Lithium ions have a potent and selective inhibitory effect on cyclic GMP formation stimulated by neurotensin, angiotensin II and bradykinin. In: European Journal of Pharmacology. 1986 ; Vol. 126, No. 1-2. pp. 111-116.
@article{5189b9f55e8a49278d9cab275837b652,
title = "Lithium ions have a potent and selective inhibitory effect on cyclic GMP formation stimulated by neurotensin, angiotensin II and bradykinin",
abstract = "The effect of lithium ion (Li+) on receptor-mediated synthesis of cyclic GMP, a putative second messenger, was examined using intact murine neuroblastoma cells (clone N1E-115). Lithium chloride potently inhibited cyclic GMP formation stimulated by the neuropeptides, neurotensin, angiotensin II and bradykinin in an identical concentration-dependent (IC50s of around 12 mM), saturable and reversible manner. In the presence of veratridine, an alkaloid which by stimulating sodium channels can increase Li+ entry into the cells, Li+ inhibited neurotensin-stimulated cyclic GMP formation more potently (IC50 = 7 mM). No effect of Li+ was observed on phosphodiesterase (EC 3.1.4.17) activity. These results suggest that Li+ may interfere with the function of these receptors through its inhibitory effect at a common site in the pathway of receptor-mediated cyclic GMP formation.",
keywords = "Angiotensin II, Bradykinin, Cyclic GMP, Lithium, Neurotensin, Phosphodiesterase",
author = "Shigenobu Kanba and Michael Pfenning and Kanba, {Kiyoko S.} and Elliott Richelson",
year = "1986",
month = "7",
day = "15",
doi = "10.1016/0014-2999(86)90745-4",
language = "English (US)",
volume = "126",
pages = "111--116",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Lithium ions have a potent and selective inhibitory effect on cyclic GMP formation stimulated by neurotensin, angiotensin II and bradykinin

AU - Kanba, Shigenobu

AU - Pfenning, Michael

AU - Kanba, Kiyoko S.

AU - Richelson, Elliott

PY - 1986/7/15

Y1 - 1986/7/15

N2 - The effect of lithium ion (Li+) on receptor-mediated synthesis of cyclic GMP, a putative second messenger, was examined using intact murine neuroblastoma cells (clone N1E-115). Lithium chloride potently inhibited cyclic GMP formation stimulated by the neuropeptides, neurotensin, angiotensin II and bradykinin in an identical concentration-dependent (IC50s of around 12 mM), saturable and reversible manner. In the presence of veratridine, an alkaloid which by stimulating sodium channels can increase Li+ entry into the cells, Li+ inhibited neurotensin-stimulated cyclic GMP formation more potently (IC50 = 7 mM). No effect of Li+ was observed on phosphodiesterase (EC 3.1.4.17) activity. These results suggest that Li+ may interfere with the function of these receptors through its inhibitory effect at a common site in the pathway of receptor-mediated cyclic GMP formation.

AB - The effect of lithium ion (Li+) on receptor-mediated synthesis of cyclic GMP, a putative second messenger, was examined using intact murine neuroblastoma cells (clone N1E-115). Lithium chloride potently inhibited cyclic GMP formation stimulated by the neuropeptides, neurotensin, angiotensin II and bradykinin in an identical concentration-dependent (IC50s of around 12 mM), saturable and reversible manner. In the presence of veratridine, an alkaloid which by stimulating sodium channels can increase Li+ entry into the cells, Li+ inhibited neurotensin-stimulated cyclic GMP formation more potently (IC50 = 7 mM). No effect of Li+ was observed on phosphodiesterase (EC 3.1.4.17) activity. These results suggest that Li+ may interfere with the function of these receptors through its inhibitory effect at a common site in the pathway of receptor-mediated cyclic GMP formation.

KW - Angiotensin II

KW - Bradykinin

KW - Cyclic GMP

KW - Lithium

KW - Neurotensin

KW - Phosphodiesterase

UR - http://www.scopus.com/inward/record.url?scp=0022447408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022447408&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(86)90745-4

DO - 10.1016/0014-2999(86)90745-4

M3 - Article

VL - 126

SP - 111

EP - 116

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-2

ER -